盐酸氨溴索在足月重度窒息新生儿呼吸窘迫综合征中的临床疗效观察

目的探讨氨溴索注射液治疗足月重度窒息新生儿呼吸窘迫综合征（ARDS）的疗效。方法将足月重度窒息新生儿确诊为ARDS的足月新生儿30例，随机分为对照组和治疗组，两组均给予基础对症治疗，治疗组加用氨溴索注射液15mg静脉滴注，2次／d，共5～7d。比较两组呼吸窘迫缓解时间、并发症发生率、病死率、2周时NBNA指标、2d胸部X线好转率、需气管插管呼吸机辅助呼吸比率。结果呼吸窘迫缓解时间治疗组（3．0±1．0）d，对照组（6．0±1．4）d；发生并发症治疗组6例（37．5％），对照组10例（71．4％）；病死患儿治疗组2例（12．5％），对照组4例（28．6％）；2d时胸部X线好转治疗组10例（62．5％），对照组5例（35．7％）；2周时NBNA指标治疗组（38．14±3．4），对照组（35．47±2．16）；需气管插管机械通气治疗组25％，对照组81．82％。两组呼吸窘迫缓解时间、并发症发生率、病死率、2d时胸部X线好转率、2周时NBNA指标、需气管插管呼吸机辅助呼吸比率比较，差异均有统计学意义（P〈0．05）。结论盐酸氨溴索治疗足月重度窒息新生儿ARDS可缩短呼吸窘迫缓解时间，降低并发症和病死率，提高生存质量。

A study of clinical effect of adjuvant ambroxol in acute respiratory distress syndrome in intensive asphyxia of full - term newborns

Objective To study the effects of ambroxol as an adjuvant therapy in ARDS in intensive asphyxia of full - term newborns. Methods 30 intensive asphyxia of full - term newborns with ARDS were divided into two groups randomly. Two groups were treated with synthetical therapy but treatment group were treated with ambroxol （ 15 mg, iv, twice a day） in addition, 5 -7days. Two groups were compared with catabatie time of respiratory distress, probability of complication, death rate,the heonatal behavior heurological assessment in end of two weeks. The improved rate of the X - ray with HMD in the second day. The occurrence rates who had to receive mechanical ventilation. Results The catabatic time of respiratory distress was （ 3.0 ± 1.0） days,6 cases （ 37.5 % ） with complication,2 eases （ 12.5 % ） were dead, the heonatal behavior heurological assessment in end of two weeks was （38.14± 3.4）. The improved rate of the X -ray with HMD in the second day was 62. 5% （ 10 cases）. The occurrence rates who had to receive mechanical ventilation was 25% in treatment group. The eatabatie time of respiratory distress was （6.0 ±1.4） days, 10 cases （71.4%） with complication,4 cases（28.6% ） were dead, the heonatal behavior heurological assessment in end of two weeks was （ 35.47 ± 2. 16 ）. The improved rate of the X - ray with HMD in the second day was 35.7% （5 cases）. The occurrence rates who had to receive mechanical ventilation was 81.82% in control group. The difference in comparison of the results between treatment group and control group was very distinct （ P 〈 0. 05 ）. Conclusion Ambroxol can shorten the eatabatie time of respiratory distress and death rate and helps to survive as a adjuvant therapy for acute respiratory distress syndrome （ARDS）in intensive asphyxia of full- term newboms.